- ROUNDTABLE: Pharmacy’s future in sync with technology
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- Lipitor may be the first statin to switch to OTC
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
WILMINGTON, Del. — A federal court has ruled in favor of AstraZeneca in a case regarding a cholesterol drug, the company said.
AstraZeneca said the Court of Appeals for the Federal Circuit upheld a decision by the U.S. District Court for the District of Delaware ruling that a patent covering the drug Crestor (rosuvastatin calcium) was valid and enforceable. The patent, which expires in 2016, covers the active ingredient of Crestor.
Under the court's decision, the Food and Drug Administration can't approve generic versions of the drug made by Apotex, Aurobindo, Cobalt, Mylan, Par, Sandoz, Teva, Sun and Torrent, but those companies may seek review by the Supreme Court.